Multi-modal treatment for invasive bladder cancer has been shown to be effective, however, definitive evidence is still lacking. Learn more about combination therapies and how they affect survival. Nature Clinical Practice Oncology
Lenalidomide (Revlimid) may be associated with an increased risk for certain forms of hematologic malignancies, according to the FDA. Medscape Medical News
Dr. Kathy Miller praises an ASCO-supported study indicating patients with metastatic NSCLC who receive early palliative care live longer and have fewer symptoms than those receiving regular therapy. Medscape Hematology-Oncology
